Document is current
Any future updates will be listed below
-
Authors
Hinata, Nobuyuki
Yonese, Junji
Masui, Satoru
Nakai, Yasutomo
Shirotake, Suguru
Tatsugami, Katsunori
Inamoto, Teruo
Nozawa, Masahiro
Ueda, Kosuke
Etsunaga, Toru
Osawa, Takahiro
Uemura, Motohide
Kimura, Go
Numakura, Kazuyuki
Yamana, Kazutoshi
Miyake, Hideaki
Fukasawa, Satoshi
Ochi, Kenya
Kaneko, Hirokazu
Uemura, Hirotsugu https://orcid.org/0000-0002-3665-9523
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000033312 at UMIN JapanDocuments that mention this clinical trial
A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data
https://doi.org/10.1007/s10147-020-01692-z
-
Funding
Funding for this research was provided by:
Ono Pharmaceutical
Bristol-Myers Squibb
- License Information
-
More Information
Article History
Received: 26 December 2019
Accepted: 27 April 2020
First Online: 9 June 2020
Compliance with ethical standard
:
: Masahiro Nozawa received lecture fees from Bristol-Myers Squibb, Novartis, and Ono Pharmaceutical. Toru Etsunaga received honoraria from Bristol-Myers Squibb and Novartis. Go Kimura received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Novartis, Pfizer, Bayer, and Chugai Pharmaceutical, and research funding from Ono Pharmaceutical and Bristol-Myers Squibb. Kenya Ochi is an employee of Ono Pharmaceutical. Hirokazu Kaneko is an employee of Bristol-Myers Squibb. Hirotsugu Uemura received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, AstraZeneca, Merck Sharp & Dohme, and Janssen Pharmaceutical and research funding from Pfizer, Janssen Pharmaceutical, Taiho, AstraZeneca, Astellas Pharma, Takeda, and Ono Pharmaceutical. Nobuyuki Hinata, Junji Yonese, Satoru Masui, Yasutomo Nakai, Suguru Shirotake, Katsunori Tatsugami, Teruo Inamoto, Kosuke Ueda, Takahiro Osawa, Motohide Uemura, Kazuyuki Numakura, Kazutoshi Yamana, Hideaki Miyake, and Satoshi Fukasawa declare that they have no conflict of interest.
